The peptide industry has entered warp speed.

Regulators simply can’t keep pace.

And that gap between scientific progress and regulatory control is where most of the disruption is happening right now.

Look no further than the peptide vendor shutdown wave that’s been sweeping the industry over the past year. What happened to Peptide Sciences is a perfect encapsulation of what we’re seeing across the board: one of the largest and most well-known grey-market peptide vendors in America going offline voluntarily due to regulatory pressure, widespread quality failures, and simple market forces.

This isn’t an isolated incident. At least 10 major vendors across the peptide space have been shut down by law enforcement, raided, issued warnings, or had lawsuits levied against them since November of 2024.

And yet the scientific reality has never been brighter.

What You’ll Learn:

1. What’s Driving the Peptide Science Boom?
2. Why Regulation Is Failing to Keep Up
3. The Peptide Vendor Shutdown Wave: Behind the Headlines
4. Implications for Access To Peptides & Beyond

What’s Driving the Peptide Science Boom?

Peptide science has never been hotter.

Interest, investment, and breakthroughs in peptide research have all exploded over the past few years.

Need proof?

The global peptide therapeutics market hit $46.17 BILLION in revenue last year, and is expected to nearly DOUBLE by 2033.

That doesn’t happen without a lot of perfect conditions lining up.

Let’s break down exactly why peptides are getting so much attention:

• Breakthroughs like semaglutide and tirzepatide became household names over the past few years, bringing legitimacy to the entire peptide category.
• Compared to many small molecule drugs, peptides offer high potency with relatively low toxicity.
• Artificial intelligence & automated synthesis have drastically sped up peptide discovery and production.
• We live in an obesity/metabolic disease pandemic with sky-high demand for solutions.

FDA approvals like Ozempic & Mounjaro put peptide science on the map.

The problem?

Mainstream acceptance of prescription peptides created a massive grey market that flew entirely under the FDA’s radar.

Attracted by sky-high demand from consumers learning about peptides online, research chemical vendors, compounders, and supplement sellers began mass-producing peptides for sale directly to customers. Regulation couldn’t keep up as peptides flooded online forums, newsletters, and social media. The gap between innovation and consumer access continued widening until the FDA and DOJ paid attention.

…and when they did…it hit hard.

Why Regulation Is Failing to Keep Up

Here’s the truth about peptides and FDA regulation…

The system we have now wasn’t built for peptides.

They’re not food. They’re not supplements. And the vast majority of research peptides out there haven’t gone through the FDA drug approval process. For years, vendors used the “research use only” disclaimer on their labels to create a large but fairly unregulated grey market that flew under the FDA’s radar.

But science didn’t wait for regulations.

Peptide sequences were being invented, marketed, and sold directly to customers long before regulators had any semblance of oversight. Online peptide ads increased by 678% since 2022. Speech broke laws. Suppliers who wished to continue operating in this space started to look for solutions.

Enter: Pharma.

Big pharmaceutical companies also had no interest in seeing their highly lucrative GLP-1 products sold as cheap peptides online. It’s no coincidence that just months after Prime Peptides received their first FDA warning letter in December of 2024, Eli Lilly sued forwards its own suit against peptide vendors selling semaglutide.

The crackdown came swiftly.

Unfortunately what this means for the average consumer/vendor caught in the crossfire is regulators will likely always be “one step behind.” They’re not anti-peptide. They’re against a completely unregulated industry full of inconsistency, limited human safety data, and supplements masquerading as pharmaceuticals.

Now that you know the facts, let’s dive into exactly what happened over the past year.

The Peptide Vendor Shutdown Wave: Behind the Headlines

Here’s what you need to know. Quickly:

In late November 2023, the FDA quietly placed 19 of the most common peptides (including well known peptides) onto its Category 2 list. Which basically means compounding pharmacies are no longer allowed to repackage them for human consumption. This news came as a complete shock to the wellness community, as many clinics and providers had been using these peptides for years.

Shortly after, enforcement actions started hitting big vendors:

• December 2024: The FDA sent warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research for illegally selling semaglutide, tirzepatide, and retatrutide as prescription medications.
• June 2025: FDA agents raided Amino Asylum’s warehouse, confiscating all products and shutting them down entirely.
• Sept 2025: Over 50 warning letters had been issued to vendors selling GLP-1 peptides.

Suddenly “research use only” isn’t looking so great.

Fast forward to January 2026.

Peptide Sciences posts on Instagram that they are shutting down. After years of selling peptides online without repercussions, they decided to close up shop voluntarily. Weeks later…

HHS Secretary Robert F Kennedy Junior announces that FDA will be moving nearly half of the peptides on the Category 2 list back to category 1.

Translation: peptides like BPC157 could be available from your local compounding pharmacy again very soon.

Got all that? Here’s what it means for people actually using or wanting to use peptides.

Implications For Access To Peptides & Beyond

So where does that leave someone who has been following this saga and potentially uses peptides or is curious about trying them?

First off, the shutdowns aren’t limiting access to peptides. Instead they are redirecting it.

• Purchasing peptides from the grey market has significant legal and safety risks. If you buy peptides from sketchy websites overseas now, there’s a good chance those peptides will be counterfeit at best and dangerously tainted at worst. Not to mention you could face legal repercussions down the line.
• The legal alternative is compounded pharmacies. As soon as reclassification hits, peptides that made the cut will be available from licensed compounding pharmacies that require a valid prescription from your doctor.
• Telehealth makes that process easier than ever. Seeing a doctor online is faster and cheaper than you might think. Access to legitimate, regulated peptides is easier than ever if you choose that route.
• Big Pharma is getting wise to the threat of peptides. Not only did Eli Lilly send cease and desist letters to peptide vendors selling semaglutide last year, they filed an ITC complaint to prevent sellers from importing peptides manufactured overseas. Competing in that space is going to get much harder.

For anyone who cares about putting high quality, transparent ingredients into their body, peptides have incredible potential, but aren’t quite there just yet. The good news is that restructuring how peptides are made available to consumers doesn’t change that science. It just means knowing who you can trust.

Where Do We Go From Here?

Anyone who has been paying attention knows…the peptide industry is changing.

There are peptide sequences out there with real science behind them. Yes, even BPC157. That doesn’t mean being uncritical of companies selling everything under the sun as a “research supplement.” Regulatory crackdowns are here to stay, and will only continue until there is more structure around peptide distribution.

Peptide compounds that have demonstrated promise in legitimate research will become more accessible than ever before. Compounded peptides from licensed pharmacies will require a prescription, much like normal drugs.

And that’s actually a great thing for people who care about their health.

Last modified: March 23, 2026